CD274 and acute myeloid leukemia: Several drugs targeting this pathway, blocking PD1 (Nivolumab, Pembrolizumab, and Cemiplimab) or PDL1 (Atezolizumab, Avelumab, and Durvalumab), have been successfully tested and approved by the FDA in solid cancers and hematologic malignancies [89,111], although none of these have been approved for AML.